Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

New data reveal sharp growth in Ozempic prescribing across the country, reflecting the rising demand for GLP-1 therapies

Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

New research suggests the clinical benefits of GLP-1 therapies have yet to translate into near-term medical cost savings

Only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years

Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...

The 2026 Medical Pharmacy Trend Report: Part 1– Payer Survey reflects Prime Therapeutics’ long standing commitment to delivering trusted, data driven perspectives that shape the industry...

Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

Real-world data reveal a persistent challenge: helping patients maintain GLP-1 treatment long enough to realize its full benefits

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

Generic Name Brand Name Brand Manufacturer Indication Approval Month* chikungunya vaccine, live Ixchiq® Valneva Austria Prevention of disease caused by Chikungunya virus November meningococcal...

Editor-In-Chief: Maryam Tabatabai, PharmD Executive Editor: Anna Schreck Bird, PharmD Deputy Editors: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES A retrospective propensity score-matched cohort...

The event emphasizes additional measures for obesity therapy.

Prime Therapeutics researchers share more about award-winning real-world research